Literature DB >> 9815541

Prostate-specific membrane antigen expression in normal and malignant human tissues.

D A Silver1, I Pellicer, W R Fair, W D Heston, C Cordon-Cardo.   

Abstract

Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium. The expression of this molecule has also been documented in extraprostatic tissues, including small bowel and brain. In the present study, an extensive immunohistochemical analysis was performed on a panel of well-characterized normal and malignant human tissues to further define the pattern of prostate-specific membrane antigen (PSMA) expression. Detectable PSMA levels were identified in prostatic epithelium, duodenal mucosa, and a subset of proximal renal tubules. A subpopulation of neuroendocrine cells in the colonic crypts also exhibited PSMA immunoreactivity. All other normal tissues, including cerebral cortex and cerebellum, had undetectable levels of PSMA. Thirty-three of 35 primary prostate adenocarcinomas and 7 of 8 lymph node metastases displayed tumor cell PSMA immunostaining. Eight of 18 prostate tumors metastatic to bone expressed PSMA. All of the other nonprostatic primary tumors studied had undetectable PSMA levels. However, intense staining was observed in endothelial cells of capillary vessels in peritumoral and endotumoral areas of certain malignancies, including 8 of 17 renal cell carcinomas, 7 of 13 transitional cell carcinomas, and 3 of 19 colon carcinomas. Extraprostatic PSMA expression appears to be highly restricted. Nevertheless, its diverse anatomical distribution implies a broader functional significance than previously suspected. The decrease in PSMA immunoreactivity noted in advanced prostate cancer suggests that expression of this molecule may be linked to the degree of tumor differentiation. The neoexpression of PSMA in endothelial cells of capillary beds in certain tumors may be related to tumor angiogenesis and suggests a potential mechanism for specific targeting of tumor neovasculature.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9815541

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  474 in total

1.  Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices.

Authors:  Steven M Santana; He Liu; Neil H Bander; Jason P Gleghorn; Brian J Kirby
Journal:  Biomed Microdevices       Date:  2012-04       Impact factor: 2.838

2.  Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2011-05-05       Impact factor: 4.774

3.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

4.  NKX3.1 as a marker of prostatic origin in metastatic tumors.

Authors:  Bora Gurel; Tehmina Z Ali; Elizabeth A Montgomery; Shahnaz Begum; Jessica Hicks; Michael Goggins; Charles G Eberhart; Douglas P Clark; Charles J Bieberich; Jonathan I Epstein; Angelo M De Marzo
Journal:  Am J Surg Pathol       Date:  2010-08       Impact factor: 6.394

Review 5.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

6.  Indium-111 Capromab Pendetide (ProstaScint(®)) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma.

Authors:  Tanvir Rizvi; Chunli Deng; Patrice K Rehm
Journal:  World J Nucl Med       Date:  2015 Sep-Dec

7.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

8.  (68)Ga-PSMA-HBED-CC PET/CT: where molecular imaging has an edge over morphological imaging.

Authors:  Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03       Impact factor: 9.236

9.  Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.

Authors:  Nam-Kyung Lee; Yang Su; Scott Bidlingmaier; Bin Liu
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

10.  68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.

Authors:  Thomas A Hope; Charles Truillet; Eric C Ehman; Ali Afshar-Oromieh; Rahul Aggarwal; Charles J Ryan; Peter R Carroll; Eric J Small; Michael J Evans
Journal:  J Nucl Med       Date:  2016-09-22       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.